South Africa's Enduring Battle Against Tuberculosis

Mycobacterium tuberculosis (Mtb), the bacterium responsible for tuberculosis (TB), remains one of the most formidable infectious diseases globally, particularly in South Africa. This nation consistently ranks among the top countries for TB incidence and mortality, driven largely by the intersection with human immunodeficiency virus (HIV) co-infection. In 2024 alone, an estimated 54,000 people died from TB-related causes in South Africa, with 29,000 of those among individuals living with HIV. The National TB Recovery Plan 4.0, spanning April 2025 to March 2026, underscores the urgency, aiming to reduce incidence through enhanced diagnostics, treatment, and prevention amid ongoing challenges like drug-resistant strains.

South African universities play a pivotal role in this fight, producing cutting-edge research that not only illuminates TB's cunning survival strategies but also paves the way for innovative interventions. Recent advancements from institutions like the University of Cape Town (UCT) are shedding light on how TB manipulates the very immune defenses meant to eradicate it.

Groundbreaking UCT Discovery: TB Hijacks Dectin-1 Receptor

A landmark study published on January 26, 2026, in Science Immunology has unveiled a novel mechanism by which Mtb hijacks the immune system. Researchers from UCT, in collaboration with global partners, demonstrated that Mtb exploits the Dectin-1 receptor—a C-type lectin typically crucial for defending against fungal infections—to promote its own survival inside host cells.

The paper, titled "Mycobacterial α-glucans hijack Dectin-1 to facilitate intracellular bacterial survival" (DOI: 10.1126/sciimmunol.adw0732), reveals how this immune hijacking allows TB to thrive within macrophages, the lung's frontline immune cells. This finding is particularly resonant in South Africa, where TB claims thousands of lives annually despite decades of research efforts.Read the full UCT announcement | Access the Science Immunology paper

Step-by-Step: How Tuberculosis Immune Hijacking Unfolds

To grasp this sophisticated evasion tactic, consider the infection process:

1. Inhalation: Mtb-laden droplets enter the lungs and are engulfed by alveolar macrophages.
2. Recognition Failure: Normally, macrophages fuse phagosomes with lysosomes to destroy invaders, but Mtb prevents this.
3. Alpha-Glucan Deployment: Mtb secretes alpha-glucan, a unique polysaccharide that binds to Dectin-1 on macrophage surfaces.
4. Detrimental Signaling: Dectin-1 activation triggers inflammatory pathways that, counterintuitively, suppress effective bacterial killing, allowing Mtb replication.
5. Persistence: The bacteria establish a niche, leading to latent or active disease.

Experiments showed that cells or mice lacking Dectin-1 controlled Mtb far better, highlighting this pathway's exploitable vulnerability.

This mechanism exemplifies TB's evolutionary mastery over host immunity, a focus of intense scrutiny in South African academic labs.

Spotlight on UCT Researchers and International Collaboration

Leading the South African contingent is Associate Professor Claire Hoving from UCT's Division of Immunology in the Department of Pathology and an associate member of the Institute of Infectious Disease and Molecular Medicine (IDM). Her team integrated expertise with international collaborators: Dr. Max Gutierrez (Francis Crick Institute), Professor Sho Yamasaki (Osaka University), and Professor Gordon Brown (University of Exeter’s MRC Centre for Medical Mycology). Funded by Wellcome and the UK Medical Research Council, this partnership exemplifies how South African higher education drives global TB solutions.

"Our discovery of a new mechanism by which Mycobacterium tuberculosis is able to subvert host immunity is a key step in understanding the basis of susceptibility to TB," noted Dr. Gutierrez. Hoving emphasized the value of such alliances: "This research is a true international collaboration... required to tackle some of the greatest health challenges."

For aspiring researchers, UCT's IDM offers fertile ground; explore research jobs or clinical research positions to contribute.

From Lab Experiments to In Vivo Validation

The study's rigor combined in vitro human and mouse macrophage assays with in vivo mouse models deficient in Dectin-1. Absence of the receptor or its pathway markedly reduced Mtb loads, proving its role in pathogenesis. Alpha-glucan's direct interaction with Dectin-1 was confirmed, distinguishing it from fungal ligands where the receptor aids clearance.

These findings build on prior South African work, like SATVI-led studies at UCT revealing 80% of adult TB cases are asymptomatic, complicating detection.

TB's Broader Immune Evasion Arsenal

Beyond Dectin-1, Mtb employs multifaceted strategies:

• Inhibiting phagosome-lysosome fusion.
• Manipulating cytokine production to dampen T-cell responses.
• Inducing regulatory T-cells for tolerance.
• Surviving within necrotic granulomas.

South African reviews highlight these, urging host-directed therapies (HDTs) to reprogram immunity. Wits University's real-world data analyses further map HIV-TB dynamics.

South African Universities at the Forefront

UCT's IDM and SATVI spearhead vaccine trials and diagnostics. Stellenbosch University advances drug resistance studies, while the University of the Witwatersrand (Wits) excels in epidemiology and biostatistics for TB-HIV. Recent 2025-2026 outputs include pediatric TB trends in Western Cape and community-driven education pilots.

These institutions foster talent; check South Africa university jobs or research assistant roles for entry points.

The HIV-TB Synergy: A Unique South African Challenge

Over half of SA TB cases occur in HIV-positive individuals, impairing macrophage function and CD4 T-cell responses. The 2025 NSP for HIV, TB, and STIs targets this overlap. Immune hijacking exacerbates vulnerability, but integrated antiretroviral therapy (ART) scale-up has curbed rises.

Therapeutic Horizons: Targeting the Hijack

Blocking Dectin-1 or alpha-glucan could enhance clearance, inspiring HDTs, vaccines, or adjunct therapies. Professor Brown's vision includes receptor knockouts in cattle to curb zoonotic spread, adaptable to humans. SA's TB Recovery Plan aligns with such innovations.

• Potential Dectin-1 inhibitors.
• Alpha-glucan blockers.
• Reprogramming macrophages.

Optimism grows for shorter regimens and preventives. For career advice, see how to craft an academic CV.

Overcoming Research Hurdles in South Africa

Funding cuts threaten TB/HIV studies, yet resilience prevails. Drug resistance, diagnostics gaps, and asymptomatic spread persist. Higher ed must innovate amid these.

Looking Ahead: A Collaborative Future

With Keystone Symposia in Cape Town (March 2026), SA remains central. Global-south leadership promises breakthroughs. Aspiring academics, join via higher ed jobs.

Photo by CDC on Unsplash

Careers in TB Research: Join South Africa's Vanguard

From postdocs to faculty, opportunities abound at UCT, Wits. Explore university jobs, postdoc positions, and rate professors for insights. Career advice resources empower your path. Engage, research, impact.